Key facts
- It has raised $249.6M across 2 recorded rounds; the latest was PIPE ($175.0M) in Jul 2025.
- SAb Biotherapeutics has filed 2 Form Ds with the SEC since 2023, most recently Aug 2025 ($175.0M sold to 17 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for SAb Biotherapeutics
Create free account
No card required
Funding rounds
2 roundsJul 2025PIPE$175.0M▮
Nov 2023PIPE$74.6M▮
About SAb Biotherapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
SAb Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in SAb Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on SAb Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.